Phase Ib Study of Rocbrutinib in Combination with R-CHOP in Patients with Newly Diagnosed B-cell Non-Hodgkin Lymphoma

orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.

375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.

750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.

100 mg orally once on Day 1 to Day 5 in a 21-day cycle for six cycles.